WASHINGTON (Reuters) - The U.S. Food and Drug Administration has expanded the authorized use of Celgene Corp's cancer drug Revlimid to include newly diagnosed patients with multiple myeloma, the company said on Wednesday.
Previously the drug was only approved for patients who had received at least one previous therapy. Physicians in the United States have long been prescribing Revlimid for new patients on an "off-label" basis, but the company had not been allowed to promote its use in this population.
21:52 Netflix nears 94 million subscribers 10 years after streaming launch9
16:50 Goldman Sachs, Citigroup earnings confirm Trump effect on banks12
18:21 Mark Zuckerberg takes the stand in $2 billion lawsuit claiming Oculus theft7
16:16 Luxottica, Essilor $24 billion merger creates eyewear giant18